This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

ESMO, Barcelona, Spain 26-30 September 2019

Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: a prospective non-interventional study in EGFR-mutated NSCLC patients in Germany  

Wolfgang Brück, Martin Reck, Barbara Hermes, Eckart Laack, Justyna Rawluk, Rudolf M. Huber, Christopher Hoffmann, Andrea Schüler
Esmo Gideon NIS Poster

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Effectiveness of afatinib in the clinical practice - first results of the GIDEON trial: ​a prospective non-interventional study in EGFR-mutated NSCLC in Germany

 

Wolfgang M. Brueckl, Eckart Laack, Martin Reck, Frank Griesinger, Helmut Schäfer, Cornelius Kortsik, Tobias Gaska, Justyna Rawluk, Stefan Krüger, Konrad Kokowski, Stephan Budweiser, Andrea Schueler, Stephan Kiessling

esmo_2018_gideon_poster_final.jpg

RELATED INFORMATION

Afatinib

Afatinib (GIOTRIF®) as monotherapy is approved for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

ESMO 2019 Congress

Find information on Boehringer Ingelheim’s activities at ESMO 2019

Related information

GIDEON: a non-interventional study of the effectiveness and tolerability of afatinib in Germany
Back to top

FOR HEALTHCARE PROFESSIONALS ONLY

links_to_3rd_party.jpg